Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2026 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de serviceAcceptable Use
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to Reports
Biotech

Seattle Genetics

Seattle Genetics raises $35B Public at $38B valuation

21823 30th Drive SE, Bothell, WA 98021January 1, 20241 min read
Total Raised
$35B
Valuation
$38B
Latest Round
Public
Employees
2000+

Seattle Genetics: Public Funding Round

Seattle Genetics has successfully raised $35B in Public funding, reaching a valuation of $38B.

Company Overview

Biotechnology company

Funding Details

The Public round was led by Public.

Company Information

  • Headquarters: 21823 30th Drive SE, Bothell, WA 98021
  • Founded: 1998
  • Employees: 2000+
  • Category: Biotech

Investment

Seattle Genetics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Public: Verified investor in Public

Company Info

Headquarters
21823 30th Drive SE, Bothell, WA 98021
Founded
1998
Team Size
2000+
Last Round
$35B(Jan 2024)

Investors (1)

P
PublicLead
Lead Investor
Verified investor in Public

Topics

verified(3079)real-funding(3079)public(927)seattle-geneticsbiotech21823-30th-drive-se

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free